JOHN C. BYRD, M.D.
Osteopathic Medicine at 10 Ave, Columbus, OH

2005019, Sep 1, 2005

Nov 3, 2003

10/700264

John Byrd - Columbus OH, US
Nyla Heerema - Columbus OH, US

C12Q001/68, G01N033/574

435006000, 435007230

Methods and kits are provided for predicting the response of patients with B-cell chronic lymphocytic leukemia (CLL) to treatment with agents that bind to the CD20 and CD 52 antigens on the surface of B lymphocytes. The methods of the present invention are for identifying patients who are refractory and patients who are responsive to therapy with such agents by analyzing the genome of cells obtained from the patients for the presence of specific chromosomal abnormalities, including del(17p13.1), and one or more of del(13q14.3), del(11q22.3) and trisomy 12. The methods are performed using appropriate cytogenetic analysis techniques, such as fluorescence in situ hybridization (FISH), with probes capable of detecting the specific cytogenetic abnormalities. Patients without del(17p13.1) but with del(13q14.3), del(11q22.3) or trisomy for chromosome 12, have been shown to be responsive to agents that bind CD20, such as rituximab. Patients with del(17p13.1) have been shown not to be responsive to rituximab, but are responsive to agents that bind CD52, such as alemtuzumab. By customizing treatment of CLL based on a patient's cytogenetic profile, an improved Outcome may be achieved for the patient, along with time and cost savings that are afforded by foregoing unnecessary therapy.

8119101, Feb 21, 2012

May 28, 2010

12/789575

John C. Byrd - Columbus OH, US
David M. Goldenberg - Mendham NJ, US
Hans J. Hansen - Picayune MS, US

The Ohio State University - Columbus OH
Immunomedics, Inc. - Morris Plains NJ

A61K 39/44, A61K 51/12, A61K 9/127, A61K 39/00

424 121, 4241781, 4241791, 424450, 4241801, 4241821

Disclosed are compositions that include anti-CD74 immunoconjugates and optionally a therapeutic and/or diagnostic agent. In preferred embodiments, the immunoconjugates comprise one or more anti-CD74 antibodies or antigen-binding fragments thereof, conjugated to a liposome or micelle. Also disclosed are methods for preparing the immunoconjugates and using the immunoconjugates in diagnostic and therapeutic procedures. In certain preferred embodiments, the therapeutic methods comprise administering to a subject with a CD74-expressing disease an anti-CD74 immunoconjugate and thereby inducing apoptosis of CD74-expressing cells. In more preferred embodiments, the CD74 immunoconjugate is capable of inducing cell death in the absence of any other therapeutic agent, although such agents may be optionally administered prior to, together with or subsequent to administration of the anti-CD74 immunoconjugate. The compositions may be part of a kit for administering the anti-CD74 immunoconjugates or compositions.

2014000, Jan 2, 2014

Nov 7, 2011

13/883862

John C. Byrd - Columbus OH, US
Amy J. Johnson - Columbus OH, US
Emilia Mahoney - Columbus OH, US
David M. Lucas - Hilliard OH, US
Michael R. Grever - Powell OH, US

THE OHIO STATE UNIVERSITY - Columbus OH

A61K 31/4706, A61K 31/343, A61K 31/453, A61K 48/00

514 44 A, 514313, 435375, 435366, 514468, 514320

A method of (a) treating a lymphoproliferative disease in a subject in need thereof; (b) slowing the progression of lymphoproliferative disease in a subject who has been diagnosed with a lymphoproliferative disease; or (c) preventing or delaying development of a lymphoproliferative disease in a subject who is at risk of developing a lymphoproliferative disease. The method generally comprises administering to the individual an effective amount of a combination therapy comprising: i) at least one autophagy modulating agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof; and ii) at least one CDK inhibitor agent, or a derivative, pharmaceutically acceptable salt thereof, or prodrug thereof, wherein the i) agent and the ii) agents are administered in amounts sufficient to enhance the cytotoxicity of the combination relative to the CDK inhibitor agent treatment alone.

2008002, Jan 31, 2008

Aug 20, 2007

11/841241

Jose-Ramon SUAREZ - Neshanic Station NJ, US
John BYRD - Columbus OH, US
Michael GREVER - Powell OH, US
James DALTON - Columbus OH, US
Thomas LIN - Columbus OH, US

AVENTIS PHARMACEUTICALS INC. - Bridgewater NJ
OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH

A61K 31/452

514320000

A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention.

2011002, Feb 3, 2011

Mar 31, 2009

12/935775

Kenneth K. Chan - Dublin OH, US
Zhongfa Liu - Worthington OH, US
Zhiliang Xie - Columbus OH, US
Guido Marcucci - Powell OH, US
John C. Byrd - Columbus OH, US
Natarajan Muthusamy - Galloway OH, US
Ramiro Garzon - Columbus OH, US
Shujun Lui - Dublin OH, US

THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH

C12Q 1/68, C07H 21/04

435 6, 536 231, 536 243, 536 245

Described herein is a method for the qualitative and/or quantitative determination of an analyte in a test sample which includes base pairing at least one oligonucleotide to a capture template having an overhang; and, hybridizing with a detection probe.

2011025, Oct 13, 2011

Dec 16, 2010

12/970550

Jose-Ramon SUAREZ - Neshanic Station NJ, US
John BYRD - Columbus OH, US
Michael GREVER - Powell OH, US
James DALTON - Columbus OH, US
Thomas LIN - Columbus OH, US

OHIO STATE UNIVERSITY RESEARCH FOUNDATION - Columbus OH
AVENTIS PHARMACEUTICALS INC. - Bridgewater NJ

A61K 31/453, A61P 35/00

514320

A dosing regimen comprising a therapeutically effective amount of flavopiridol or a pharmaceutically acceptable salt thereof optionally in combination with a pharmaceutically acceptable carrier suitable for bolus infusion and subsequently for infusion is disclosed and claimed. Also disclosed and claimed is a method of treating a variety of cancers in a patient comprising administering to said patient the dosing regimen of the invention.

8309768, Nov 13, 2012

Nov 29, 2011

13/305927

Ching-Shih Chen - Upper Arlington OH, US
Samuel K. Kulp - Hillard OH, US
Dasheng Wang - Dublin OH, US
John C. Byrd - Columbus OH, US
Natarajan Muthusamy - Galloway OH, US

The Ohio State University Research Foundation - Columbus OH

C07C 215/00, C07C 211/00, C07C 213/00

564355, 564336, 564347

A number of FTY720-derived compounds with antitumor activity are described. These compounds include the compounds of formula I:.